IPSC0051, LRRK2 R1441H(CBIGi039-A) correction
The cell line is not validated yet.
CBIGi039-A-1
General
Cell Line |
|
| hPSCreg name | CBIGi039-A-1 |
| Cite as: | CBIGi039-A-1 |
| Alternative name(s) |
IPSC0051, LRRK2 R1441H(CBIGi039-A) correction
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi039-A (IPSC0050, LRRK2 R1441H(CBIGi039-A)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi044-A-1 (IPSC0059, LRRK2 N551K (CBIGi044-A) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi044-A-2 (IPSC0060, LRRK2 R1398H (CBIGi044-A) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi013-A-1 (LRRK2 M1646T correction, IPSC0018) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi027-A-1 (IPSC0039, LRRK2 G2385R (CBIGi027) correction) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease CBIGi037-A (IPSC0048, LRRK2 M1646T(CBIGi037-A)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi040-A (IPSC0052, LRRK2 N551K-R1398H-K1423K (protective haplotype) (CBIGi040-A)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi044-A (LRRK2 N551K-R1398H-K1423K (protective haplotype)(CBIGi044-A), IPSC0058) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi005-A (IPSC0003, LRRK2 G2019S) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi013-A (IPSC0017, LRRK2 M1646T (heterozygous)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi015-A (IPSC0020, LRRK2 N551K-R1398H-K1423K (protective haplotype)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi027-A (LRRK2 G2385R (CBIGi027), IPSC0037) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi001-A-45 (LRRK2-KO/AIW002-02, IPSC0117) STBCi026-A-1 (SFC840-03-03 LRRK2-/-D10) STBCi026-A-2 (SFC840-03-03 LRRK2-/-C11) STBCi026-A-3 (SFC840-03-03 LRRK2 WT/R1441C H3) CBIGi041-A-1 (IPSC0054, GBA L444P (CBIGi041-A) correction) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease |
| Last update | 30th July 2025 |
| Notes | Isogenic control for CBIGi0039-A. |
| User feedback | |
Provider |
|
| Generator | Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) |
| Distributors | |
| Derivation country | Canada |
External Databases |
|
| BioSamples | SAMEA117982033 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Creole Haitian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA117982032 |
Ethics
Also have a look at the ethics information for the parental line
CBIGi039-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CBIGi039-A.
|
|
| Passage number reprogrammed | P17 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
| Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal 46, XY
Passage number: P17
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.